| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Jan 2025 | 23 Dec 2024 |
| DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2024. Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on January 23, 2025, has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025) | ||
| Board Meeting | 5 Nov 2024 | 22 Sep 2024 |
| DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2024 Board of Directors of the Company at its meeting held on November 5, 2024, has inter alia approved the following: 1. Financial results a. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b. Press Release on Unaudited Financial Results of the Company for the above period. c. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, as per Indian Accounting Standards. d. Unaudited Standalone Financial Results of the Company for the quarter and half-year ended September 30, 2024, as per Indian Accounting Standards. Pursuant to Regulation 33 of the SEBI Listing Regulations, the Limited Review Reports of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results as mentioned at serial nos. (c) & (d) are also enclosed. 2. Investment in step-down wholly owned subsidiary company Approval of the fund infusion by way of investment in equity shares of Dr. Reddys Laboratories LLC, Russia, a step-down wholly-owned subsidiary, upto an amount of Rs.600 Crores. The fund will be used for working capital requirements. The requisite details as required under SEBI Listing Regulations, read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, will be disclosed to the stock exchange(s) after approval of the Board of the said step-down wholly-owned subsidiary. (As Per BSE Announcement Dated on 05.11.2024) | ||
| Board Meeting | 27 Jul 2024 | 21 Jun 2024 |
| DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30 2024 Outcome of Board Meeting (As Per BSE Announcement dated on 27.07.2024) | ||
| Board Meeting | 7 May 2024 | 22 Mar 2024 |
| DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2024 and to recommend dividend If any for the financial year 2023-24. Audited Financial results for the quarter and year ended March 31, 2024 Outcome of Board Meeting - Audited Financial Results for the quarter and year ended March 31, 2024 Dividend updates Change in Key Managerial Personnel 40th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, July 29, 2024 The Register of members and the Share Transfer books of the Company shall remain closed from Wednesday, July 17, 2024 to Friday, July 19, 2024 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company (As Per BSE Announcement Dated on 07.05.2024) | ||
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
